US Patent

US12161767 — Systems and methods for long term transdermal administration

Method of Use · Assigned to Corium LLC · Expires 2036-12-30 · 11y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects systems and methods for the long-term transdermal administration of an active agent.

USPTO Abstract

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Drugs covered by this patent

donepezil-hydrochloride (DONEPEZIL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3334`	—	donepezil-hydrochloride
`U-3334`	—	donepezil-hydrochloride

Patent Metadata

Patent number: US12161767
Jurisdiction: US
Classification: Method of Use
Expires: 2036-12-30
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Corium LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.